uniQure N.V. (QURE) |
|
22.82 -0.1 (-0.44%)
|
02-08 09:41 |
|
Open: |
22.9 |
Pre. Close: |
22.92 |
|
High:
|
22.9 |
Low:
|
22.7 |
|
Volume:
|
9,963 |
Market Cap:
|
1,068(M) |
|
|
|
Technical analysis |
as of: 2023-02-07 4:31:16 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 27.4 One year: 32 |
| Support: |
Support1: 21.74 Support2: 20.69 |
| Resistance: |
Resistance1: 23.45 Resistance2: 27.4 |
| Pivot: |
21.74  |
| Moving Average: |
MA(5): 22.38 MA(20): 21.83
MA(100): 21.27 MA(250): 19.35 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 70.9 %D(3): 62.8 |
| RSI: |
RSI(14): 56.9 |
| 52-week: |
High: 28.25 Low: 12.52 |
| Average Vol(K): |
3-Month: 697 (K) 10-Days: 417 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ QURE ] has closed Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
23.02 - 23.11 |
23.11 - 23.19 |
|
Low:
|
22.09 - 22.2 |
22.2 - 22.3 |
|
Close:
|
22.72 - 22.91 |
22.91 - 23.07 |
|
Company Description |
|
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. |
Headline News |
Wed, 08 Feb 2023
Rising Trends of Telehealth Market will Witness Substantial Growth ... - Digital Journal
Tue, 07 Feb 2023
Feedback encouraged by interest in Bleepa and Carelocker in NHS ... - Proactive Investors UK
Thu, 02 Feb 2023
Barclays PLC Purchases 129286 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Tue, 31 Jan 2023
Health Care Sector Update for 01/31/2023: HILS, QURE, SILO - Nasdaq
Tue, 31 Jan 2023
QURE stock gains as uniQure inks licensing deal for ALS candidate ... - Seeking Alpha
Fri, 20 Jan 2023
Paula Soteropoulos Sells 6000 Shares of uniQure (NASDAQ:QURE ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
46 (M) |
| Shares Float |
35 (M) |
|
% Held by Insiders
|
7 (%) |
|
% Held by Institutions
|
91.3 (%) |
|
Shares Short
|
3,000 (K) |
|
Shares Short P.Month
|
2,960 (K) |
Stock Financials |
|
EPS
|
-2.81 |
|
EPS Est Next Qtl
|
-0.7 |
|
EPS Est This Year
|
-2.98 |
|
EPS Est Next Year
|
-2.66 |
|
Book Value (p.s.)
|
5.44 |
|
Profit Margin (%)
|
-184.1 |
|
Operating Margin (%)
|
-235.6 |
|
Return on Assets (ttm)
|
-12.3 |
|
Return on Equity (ttm)
|
-20.4 |
|
Qtrly Rev. Growth
|
-100 |
|
Gross Profit (p.s.)
|
7.83 |
|
Sales Per Share
|
1.34 |
|
EBITDA (p.s.)
|
-3 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-129 (M) |
|
Levered Free Cash Flow
|
-86 (M) |
Stock Valuations |
|
PE Ratio
|
-8.16 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
4.2 |
|
Price to Sales
|
17.09 |
|
Price to Cash Flow
|
-8.24 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
